ASCO 2021 Ovarian Cancer | Physician's Weekly
Advertisement

ASCO 2021 Ovarian Cancer

Novel drug combination for recurrent ovarian cancer

Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial....

Advertisement

For latest news and updates
Email-id is invalid